First Line Medical Treatment of Metastatic Renal Cell Carcinoma: A Podcast on Choosing Wisely and Managing Safely
AbstractDuring the last 15  years, tremendous efforts have been made toward medical treatment of metastatic renal cell carcinoma (mRCC). Checkpoint inhibitors (CPI) and tyrosine kinase inhibitors (TKI) dominate the therapeutic armamentarium, as a combination of either CPIs or CPI/TKI, while the value of TKI monotherapy is de creasing. With increasing efficiency, however, toxicity also increases. Appropriate management of adverse events is therefore pivotal. Recognizing adverse events, judging their etiology and appropriate management, and sometimes expanding the diagnostics of adverse events are mandatory and demand exp e...
Source: Advances in Therapy - August 16, 2023 Category: Drugs & Pharmacology Source Type: research

Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
(Source: Advances in Therapy)
Source: Advances in Therapy - August 16, 2023 Category: Drugs & Pharmacology Source Type: research

Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
AbstractBrain metastases are especially common in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with a cumulative incidence of over 50% and associated with a poor prognosis, high symptom burden, and decreased quality of life. Lorlatinib is a brain-penetrant, third-generation ALK tyrosine kinase inhibitor (TKI), which has a high potency against resistance mutations seen with earlier generation ALK TKIs. In 2018, lorlatinib was granted accelerated approval in second- and third-line treatment for use in patients withALK-positive metastatic NSCLC on the basis of phase  1/2 study results. This i...
Source: Advances in Therapy - August 12, 2023 Category: Drugs & Pharmacology Source Type: research

Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours
ConclusionThe results identified key features of injection devices for SRL therapy which merit consideration for optimal management and underscore the importance of patient partnership in treatment decisions. (Source: Advances in Therapy)
Source: Advances in Therapy - August 12, 2023 Category: Drugs & Pharmacology Source Type: research

Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
ConclusionGiven the limited real-world efficacy onEGFR-mutant NSCLC resistant to osimertinib and platinum-based chemotherapy, the development of more highly potent post-treatment therapies is warranted. (Source: Advances in Therapy)
Source: Advances in Therapy - August 12, 2023 Category: Drugs & Pharmacology Source Type: research

Uterine Fibroids: A Podcast on Patient and Physician Perspectives on Medical Management and a New Medical Therapy (Relugolix Combination Therapy)
AbstractUterine fibroids (UF) are common benign tumors in women and are an important health concern in the US and globally. UF can severely compromise a woman's quality of life, thus making it an important health issue. In this podcast, a professor of Obstetrics and Gynecology, University of Chicago (Dr. Ayman Al-Hendy) and the CEO of the Fibroid Foundation (Sateria Venable) provide their perspectives on the diagnosis and management of UF, including common treatments (e.g., myomectomy or hysterectomy). They also discuss Relugolix combination therapy for UF, noting who could benefit from this treatment and how it works. Pod...
Source: Advances in Therapy - August 12, 2023 Category: Drugs & Pharmacology Source Type: research

Unintended Consequences of Increased Out-of-Pocket Costs During Medicare Coverage Gap on Anticoagulant Discontinuation and Stroke
ConclusionIncreased OOP costs during Medicare coverage gap were associated with higher risk of DOAC discontinuation, which in turn was associated with higher risk of stroke and SE among beneficiaries with NVAF. (Source: Advances in Therapy)
Source: Advances in Therapy - August 11, 2023 Category: Drugs & Pharmacology Source Type: research

Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Na ïve and Treatment-experienced Adult Patients with Rheumatoid Arthritis
ConclusionTreatment choice primarily depends on disease activity and prognosis. Real-world data, showing differences in drug survival of bDMARDs and tsDMARD, can also be used in the variety of considerations when choosing treatment. Future studies could separate patients with RA into subgroups, which would also account for potential drug survival differences and enable personalized therapy. (Source: Advances in Therapy)
Source: Advances in Therapy - August 11, 2023 Category: Drugs & Pharmacology Source Type: research

Correction to: Effect of Nicorandil, Diltiazem, or Isosorbide Mononitrate for Oral Antispastic Therapy After Coronary Artery Bypass Grafting Using Radial Artery Grafts —A Pilot Randomized Controlled Trial (ASRAB-Pilot): Rationale and Study Protocol
(Source: Advances in Therapy)
Source: Advances in Therapy - August 10, 2023 Category: Drugs & Pharmacology Source Type: research

One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib
ConclusionsPatients with RA, regardless of recent TNFi experience, initiating upadacitinib were significantly more likely to be adherent and less likely to discontinue therapy compared to adalimumab, baricitinib, and tofacitinib in the first 12  months of treatment. (Source: Advances in Therapy)
Source: Advances in Therapy - August 5, 2023 Category: Drugs & Pharmacology Source Type: research

Implementing an Evidence-Based COPD Hospital Discharge Protocol: A Narrative Review and Expert Recommendations
AbstractDischarge bundles, comprising evidence-based practices to be implemented prior to discharge, aim to optimise patient outcomes. They have been recommended to address high readmission rates in patients who have been hospitalised for an exacerbation of chronic obstructive pulmonary disease (COPD). Hospital readmission is associated with increased morbidity and healthcare resource utilisation, contributing substantially to the economic burden of COPD. Previous studies suggest that COPD discharge bundles may result in fewer hospital readmissions, lower risk of mortality and improvement of patient quality of life. Howeve...
Source: Advances in Therapy - August 4, 2023 Category: Drugs & Pharmacology Source Type: research

Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims
ConclusionHRU and healthcare costs increased substantially following mCRPC diagnosis, and continued to increase even further through progression from 1L through 3L mCRPC therapy. These findings help to quantify the economic burden of mCRPC and to contextualize the economic value of treatments that delay disease progression. (Source: Advances in Therapy)
Source: Advances in Therapy - August 2, 2023 Category: Drugs & Pharmacology Source Type: research

Correction to: Pharyngeal Reconstruction Methods to Reduce the Risk of Pharyngocutaneous Fistula After Primary Total Laryngectomy: A Scoping Review
(Source: Advances in Therapy)
Source: Advances in Therapy - August 1, 2023 Category: Drugs & Pharmacology Source Type: research

The Economic Burden of Adults with Major Depressive Disorder in the United States (2019)
ConclusionsThe economic burden of MDD is substantial and extends beyond healthcare costs, underscoring the impact of MDD across multiple aspects of life. Such a broad societal perspective should be considered in assessing the impact of the advent of effective, rapid-acting MDD therapies. (Source: Advances in Therapy)
Source: Advances in Therapy - July 31, 2023 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
ConclusionNewer antidiabetic drugs as second line are the cost-effective option for T2D from the cost-effectiveness perspective, especially SGLT2i. (Source: Advances in Therapy)
Source: Advances in Therapy - July 29, 2023 Category: Drugs & Pharmacology Source Type: research